NY-ESO-1 TCR / Medigene - LARVOL DELTA

Medigene Reports Financial Results and Corporate Update for Q3 2023 (GlobeNewswire) - "Medigene AG...today reported financial results and provided a corporate update for the third quarter of 2023...Due to the prolonged funding and development pause by Hongsheng Sciences of the partnered program that included Medigene’s NY-ESO-1-targeted TCR, the parties have mutually agreed to terminate the partnership agreement as it relates to the NY-ESO-1 asset in Q3 2023....In September, the Company was granted a patent by the European Patent Office protecting its PD1-41BB costimulatory switch protein technology. The patent complements the PD1-41BB IP-portfolio with similar patents already granted in the United States, China and Japan."

Commercial • Patent • Oncology • Solid Tumor